Related Experiment Videos
[Our therapy concept in nonresectable liver metastases]
R Margreiter1, T Schmid, E Steiner
1I. Universitätsklinik für Chirurgie Innsbruck.
Wiener Medizinische Wochenschrift (1946)
|July 15, 1988
Summary
This study evaluated chemotherapy for advanced cancers. Results showed limited efficacy and significant toxicity, leading to a shift away from liver transplantation for metastases.
Area of Science:
- Oncology
- Medical Oncology
- Surgical Oncology
Context:
- Investigated cytotoxic chemotherapy regimens for advanced colonic carcinoma, breast cancer, and liver metastases.
- Assessed outcomes including clinical response, survival, and treatment-related toxicity.
- Included liver transplantation and autologous bone marrow transplantation in some patients.
Purpose:
- To evaluate the efficacy and safety of various cytotoxic chemotherapy regimens.
- To assess the role of liver transplantation in managing non-resectable liver metastases.
- To determine the feasibility of intensive post-transplant therapies.
Summary:
- 18 patients received different chemotherapy protocols including 5-Fluorouracil (5-FU), FUDR, Mitomycin C, Cyclophosphamide, and Methotrexate.
- Limited clinical response was observed, with only 2 breast cancer patients showing significant improvement.
- Liver transplantation followed by intensive therapies (e.g., high-dose Cyclophosphamide, TBI, autologous BMT) showed poor survival outcomes.
- Only 3 patients survived long-term, all with recurrent or metastatic disease, leading to the abandonment of liver transplantation for this indication.
Impact:
- Liver transplantation for non-resectable liver metastases has been discontinued due to poor outcomes.
- Current practice focuses on regional chemotherapy for liver metastases, particularly in breast cancer patients post-resection.
- Highlights the need for more effective systemic or regional therapies for advanced metastatic disease.